Table 1.

Characteristics of the 214 patients included in the study.

Characteristicsn (%)
Age at study entry, y
 Median62
 IQR (minimum–maximum)69–56 (29—87)
Gender
 Male42 (20)
 Female172 (80)
Site of primary tumor
 Ovary120 (56)
 Lung39 (18)
 Breast38 (18)
 Othera17 (8)
Chemotherapyb
 Paclitaxel 175 + carboplatin159 (74)
 Paclitaxel 8025 (12)
 Paclitaxel 150 + gemcitabine7 (3)
 Paclitaxel 90 + bevacizumab5 (2)
 Paclitaxel 80 + carboplatin5 (2)
 Paclitaxel 80 + carboplatin + trastuzumab4 (2)
 Paclitaxel 175 + cisplatin3 (1)
 Paclitaxel 80 + cetuximab2 (1)
 Paclitaxel 80 + trastuzumab2 (1)
 Paclitaxel 175 + lapatinib1 (0.4)
 FAC–FEC followed by paclitaxel 801 (0.4)
Neurotoxicityc
 Grade 061 (28)
 Grade I46 (21)
 Grade II83 (39)
 Grade III24 (11)
Treatment modificationd
 No change167 (78)
 Reduction22 (10)
 Suspension25 (12)

Abbreviations: FAC, 5-fluorouracil, Adriamycin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; IQR, interquartile range.

  • aOther sites of primary tumor were uterus, head and neck, bladder, urinary tract, germinal, and peritoneal.

  • bPaclitaxel 80 to 90 mg/m2 had mainly 1-hour infusion and 150 to 175 mg/m2 mainly 3-hours infusion. All doses in mg/m2, if not specified otherwise. The different treatments consisted of: paclitaxel 175 + carboplatin [paclitaxel 175; carboplatin area under curve (AUC) 6/3 weeks]; paclitaxel 80 (paclitaxel 80/weekly); paclitaxel 150 + gemcitabine (paclitaxel 150; gemcitabine 2,500/2 weeks); paclitaxel 90 + bevacizumab (paclitaxel 1°, 8° and 15° day; bevacizumab 10 mg/kg 1° and 15° day/4 weeks); paclitaxel 80 + carboplatin (paclitaxel 80 + carboplatin AUC 2/weekly); paclitaxel 80 + carboplatin + trastuzumab (paclitaxel 80; carboplatin AUC 2; and trastuzumab 2 mg/kg/weekly); paclitaxel 175 + cisplatin (paclitaxel 175; cisplatin 90/3 weeks); in 1 patient paclitaxel was administered intraperitoneally; paclitaxel 80 + cetuximab (paclitaxel 80; cetuximab 250/weekly); paclitaxel 80 + trastuzumab (paclitaxel 80; trastuzumab 2 mg/kg/weekly); paclitaxel 175 + lapatinib (paclitaxel 175/3 weeks; lapatinib 1,250 mg per day); and FAC–FEC followed by paclitaxel 80 (FAC/FEC followed by paclitaxel 80/weekly).

  • cMaximum neurotoxicity according to National Cancer Institute (NCI) Common Toxicity Criteria version 2.

  • dModifications of the treatment because of paclitaxel-induced neurotoxicity.